Abi-Dargham, A. (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacoly,...
Adams, C. E., y Eisenbruch, M. (2000). Depot fluphenazine for schizophrenia. Cochrane Database Systematic Reviews, CD000307.
Alberdi, J., Castro, C. y Vázquez, C. (2005). Esquizofrenia [Electronic Version]. Guías clínicas Fisterra, 5, from www.fisterra.com/guias2/...
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., et al. (2009). The 2009 schizophrenia PORT psychopharmacological...
Citrome, L. (2009). Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation...
Consenso Español de Expertos para Recomendaciones de Actuación en el Tratamiento de la Esquizofrenia. (2000). Madrid: Sociedad Española de...
Costentin, J. (2009). [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists]. Annales Pharmaceutiques Francaises,...
Dahan, L., Husum, H., Mnie-Filali, O., Arnt, J., Hertel, P. y Haddjeri, N. (2009). Effects of bifeprunox and aripiprazole on rat serotonin...
Davis, J. M., Matalon, L., Watanabe, M. D., Blake, L. y Metalon, L. (1994). Depot antipsychotic drugs. Place in therapy. Drugs, 47, 741-773.
Dawson, L. A. y Smith, P. W. (2010). Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Current Pharmaceutical...
Delay, J., Deniker, P. y Harl, J. M. (1952). Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Annales...
Dolder, C. R., Lacro, J. P., Leckband, S. y Jeste, D. V. (2003). Interventions to improve antipsychotic medication adherence: review of recent...
Fenton, W. S., Blyler, C. R. y Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings....
Fleischhacker, W. W., Keet, I. P. y Kahn, R. S. (2005). The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the...
Gastpar, M., Masiak, M., Latif, M. A., Frazzingaro, S., Medori, R. y Lombertie, E. R. (2005). Sustained improvement of clinical outcome with...
Gray, J. A. y Roth, B. L. (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin, 33, 1100-1119.
Gray, R., Leese, M., Bindman, J., Becker, T., Burti, L., David, A., et al. (2006). Adherence therapy for people with schizophrenia. European...
Grupo de trabajo de la Guía de Práctica Clínica sobre la Esquizofrenia y el Trastorno Psicótico Incipiente. Fòrum de Salut Mental, c. (2009)....
Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P. y Yao, X. (2008). Interventions for enhancing medication adherence. Cochrane Database...
Hoy, S. M., Scott, L. J. y Keating, G. M. (2010). Intramuscular paliperidone palmitate. CNS Drugs, 24, 227-244.
Hui, C., Wardwell, B. y Tsai, G. E. (2009). Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets...
Jones, C. A. y McCreary, A. C. (2008). Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology, 55, 1056-1065.
Jones, P. B., Barnes, T. R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., et al. (2006). Randomized controlled trial of the effect on...
Jufe, G. (2002). Psicofarmacología práctica. Buenos Aires: Polemos.
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., et al. (2008). Effectiveness of antipsychotic drugs...
Kantrowitz, J., Citrome, L. y Javitt, D. (2009). GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and...
Kemp, R., Hayward, P., Applewhaite, G., Everitt, B. y David, A. (1996). Compliance therapy in psychotic patients: randomised controlled trial....
Kemp, R., Kirov, G., Everitt, B., Hayward, P. y David, A. (1998). Randomised controlled trial of compliance therapy. 18-month follow-up. British...
Knapp, M., King, D., Pugner, K. y Lapuerta, P. (2004). Non-adherence to antipsychotic medication regimens: associations with resource use...
Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O., et al. (2004). Practice guideline for the...
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C. y Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs...
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic...
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., et al. (2007). Efficacy and tolerability of olanzapine,...
Mendoza, M. C. y Lindenmayer, J. P. (2009). Ndesmethylclozapine: is there evidence for its antipsychotic potential? Clinical Neuropharmacoly,...
Mikell, C. B., McKhann, G. M., Segal, S., McGovern, R. A., Wallenstein, M. B. y Moore, H. (2009). The hippocampus and nucleus accumbens as...
Miller, B. J. (2008). A review of second-generation antipsychotic discontinuation in first-episode psychosis. Journal of Psychiatric Practice,...
Novak-Grubic, V. y Tavcar, R. (2002). Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective...
Pharoah, F., Mari, J., Rathbone, J., y Wong, W. (2006). Family intervention for schizophrenia. Cochrane Database System Review, 4, CD 000088.
Pilling, S., Bebbington, P., Kuipers, E., Garety, P., Geddes, J., Orbach, G., et al. (2002). Psychological treatments in schizophrenia: I....
Radek, R. J., Kohlhaas, K. L., Rueter, L. E. y Mohler, E. G. (2010). Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal...
Roca, M., Canas, F., Olivares, J., Rodriguez, A. y Giner, J. (2007). Treatment Adherence in Schizophrenia. Spanish Clinical Consensus. Actas...
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders....
Rummel, C., Kissling, W., y Leucht, S. (2006). Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev, 3,...
Schwarcz, G., Karajgi, B. y McCarthy, R. (2009). Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia....
Stahl. (2010). Psicofarmacología Esencial de Stahl. Guía del prescriptor. (3 ed.): Aula Médica.
Taylor, D. M., Young, C. y Patel, M. X. (2006). Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors...
Tuominen, H. J., Tiihonen, J. y Wahlbeck, K. (2006). Glutamatergic drugs for schizophrenia. Cochrane Database Systematic Reviews, 2, CD003730.
Turkington, D., Kingdon, D. y Weiden, P. J. (2006). Cognitive behavior therapy for schizophrenia.
American Journal of Psychiatry, 163, 365-373. Weiden, P., Rapkin, B., Mott, T., Zygmunt, A.,
Goldman, D., Horvitz-Lennon, M., et al. (1994). Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin, 20,...
Weiden, P. J., Schooler, N. R., Weedon, J. C., Elmouchtari, A., Sunakawa, A. y Goldfinger, S. M. (2009). A randomized controlled trial of...
Zaman, R., Thind, D. y Kocmur, M. (2008). Transcranial magnetic stimulation in schizophrenia. Neuroendocrinoly Letters, 29 Suppl 1, 147- 160.
Zygmunt, A., Olfson, M., Boyer, C. A., y Mechanic, D. (2002). Interventions to improve medication adherence in schizophrenia. American Journal...
